Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIBREXIA-ACS: Milvexian in Acute Coronary Syndrome
NCT05754957Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2023
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 44
01
Overview
A Phase 3 trial of milvexian in acute coronary syndrome (ACS), sponsored by Janssen Pharmaceutical. Started Apr 2023; status: completed.
02
Drugs
milvexian
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT05754957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05754957.